CNTA241220P20000
- 0.00
- 0.000.00%
Centessa Pharmaceuticals Newsroom
Leerink Partners Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Announces Target Price $24
Centessa Pharmaceuticals Is Maintained at Buy by Guggenheim
Guggenheim Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Raises Target Price to $28
Morgan Stanley Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Raises Target Price to $27
BMO Capital Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Maintains Target Price $35
Morgan Stanley Lifts Price Target on Centessa Pharmaceuticals to $27 From $26, Keeps Overweight Rating
B.Riley Financial Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Maintains Target Price $33
Centessa Pharmaceuticals: Promising Pipeline and Strategic Focus Drive Buy Rating
Leerink Partners Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating
BMO Capital Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Maintains Target Price $35
Oppenheimer Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Maintains Target Price $24
Centessa Pharmaceuticals Raised to Overweight From Equal-Weight by Morgan Stanley
Morgan Stanley Upgrades Centessa Pharmaceuticals(CNTA.US) to Buy Rating, Raises Target Price to $26
B.Riley Financial Initiates Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Announces Target Price $33
Buy Rating for Centessa Pharmaceuticals on Promising ORX750 Drug Advancements and Market Expansion Potential
Centessa Pharmaceuticals Is Maintained at Outperform by BMO Capital
Centessa Pharmaceuticals Analyst Ratings
BMO Capital Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Raises Target Price to $35
Oppenheimer Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Raises Target Price to $24
Centessa Pharmaceuticals (CNTA) Gets a Buy From Oppenheimer